3 Health Services Stocks Nudging The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 16 points (0.1%) at 16,738 as of Wednesday, June 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,399 issues advancing vs. 1,611 declining with 145 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.1%. Top gainers within the industry include Omnicare ( OCR), up 3.2%, Smith & Nephew ( SNN), up 2.7%, Express Scripts ( ESRX), up 1.3%, Quest Diagnostics ( DGX), up 1.2% and Grifols ( GRFS), up 1.1%. A company within the industry that fell today was Boston Scientific ( BSX), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. CareFusion ( CFN) is one of the companies pushing the Health Services industry higher today. As of noon trading, CareFusion is up $0.60 (1.4%) to $43.68 on average volume. Thus far, 741,791 shares of CareFusion exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $42.95-$43.72 after having opened the day at $43.06 as compared to the previous trading day's close of $43.07.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. CareFusion has a market cap of $8.9 billion and is part of the health care sector. Shares are up 8.2% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CareFusion Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Jim Cramer: The S&P 500 Isn’t as Passive as You Might Think

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

3 Stocks Reiterated As A Buy: CFN, UTX, WHR

Insider Trading Alert - CFN, VSR And CAVM Traded By Insiders

Jim Cramer on the Stock Market: Spinoffs Are in Vogue